Anuradha Mann, MD
Internal Medicine · Columbia, TNNPI 1578531174
Payments from drug & device makers
Across 300 payments — averaging $24.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Amgen$582
- GSK$505
- Novo Nordisk$445
- AstraZeneca$351
- Lilly USA, LLC$343
- plus $3K from 24 others
What the payments were for
- Travel & lodging$1,88726%
- Food & beverage$5,26173%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 28 | $2,329 |
| Amgen | 36 | $582 |
| GSK | 28 | $505 |
| Novo Nordisk | 23 | $445 |
| AstraZeneca | 19 | $351 |
| Lilly USA, LLC | 22 | $343 |
| Boehringer Ingelheim | 21 | $317 |
| Pfizer | 15 | $286 |
| Astellas Pharma US Inc | 10 | $256 |
| Bayer | 10 | $180 |
| Novartis | 8 | $179 |
| E.r. Squibb & Sons, L.L.C. | 7 | $140 |
| Xeris Pharmaceuticals, Inc. | 10 | $135 |
| Esperion Therapeutics, Inc. | 7 | $132 |
| AbbVie | 7 | $132 |
| Exact Sciences | 7 | $127 |
| Daiichi Sankyo Inc. | 6 | $103 |
| Mylan Specialty L.p. | 4 | $79 |
| Boston Scientific | 3 | $74 |
| Phathom Pharmaceuticals, Inc. | 4 | $73 |
| Abbott | 4 | $72 |
| Philips North America LLC | 3 | $58 |
| Shield Therapeutics Inc | 3 | $56 |
| Eisai Inc. | 3 | $50 |
| Sanofi-aventis U.S. LLC | 3 | $48 |
| Merck | 3 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $45 |
| Corcept Therapeutics | 1 | $27 |
| Insulet Corporation | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VenaSeal$1,651
How this compares
$7,212 in reported general payments places this provider in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 153 | $167,457 |
| MounjaroTirzepatide | 60 | $81,220 |
| OzempicSemaglutide | 57 | $63,715 |
| EliquisApixaban | 60 | $51,964 |
| FarxigaDapagliflozin Propanediol | 76 | $47,685 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $25,261 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 27 | $21,023 |
| TrulicityDulaglutide | 20 | $18,660 |
| XareltoRivaroxaban | 12 | $17,099 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $14,053 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 21 | $12,926 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $11,398 |
| GemtesaVibegron | 14 | $9,355 |
| MyrbetriqMirabegron | 11 | $7,048 |
| Verapamil SrVerapamil Hcl | 17 | $4,171 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $317 | $167,457153 claims |
| Lilly USA, LLCMounjaro, Trulicity | $343 | $99,88080 claims |
| Novo NordiskOzempic | $445 | $63,71557 claims |
| PfizerEliquis, Paxlovid | $286 | $53,32972 claims |
| AstraZenecaFarxiga | $351 | $47,68576 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $505 | $46,47557 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $48 | $12,92621 claims |
| Astellas Pharma US IncMyrbetriq | $256 | $7,04811 claims |
| AbbVieSynthroid | $132 | $2,12533 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,216 internal medicine providers in Tennessee.
Other internal medicine in Columbia
- Mark McKenzieChattanooga$11.9M
- Bernard GrunstraBristol$6.4M
- Jewel WhiteKingsport$5.7M
- Judith WhiteKingsport$5.6M
- Obadias MarquezOoltewah$2.8M
- Amanda Moore MillerKnoxville$2.3M
- Rick WhilesBristol$1.5M
- John AndersonNashville$1.5M
- David MorinKingsport$1.4M
- John KirbyJefferson City$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.